Descripción de negocio
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR.
Consejo de gestión & Consejo de supervisión
| CEO |
| Dr. Jean-Paul Kress |
| Consejo de gestión |
| Lucinda Crabtree, Ph.D., Tim Demuth, M.D., Ph.D., Barbara Krebs-Pohl, Ph.D., Joe Horvat, Luisa Ciccarelli, Thomas Biegi, Charlotte Lohmann |
| Consejo de supervisión |
| Dr. Marc Cluzel, Dr. George Golumbeski, Krisja Vermeylen, Michael Brosnan, Sharon Curran, Andrew Cheng, M.D., Ph.D. |
Datos de la empresa
| Nombre: |
MorphoSys AG |
| Dirección: |
Semmelweisstr. 7,D-82152 Martinsried/Planegg |
| Teléfono: |
+49-89-89927-0 |
| Fax: |
+49-89-89927-222 |
| E-mail: |
info@morphosys.de
|
| Internet: |
www.morphosys.de |
| Industria: |
Biotechnology |
| Sector: |
Biotechnology |
| Subsector: |
Biotechnology |
| Fin del año financiero: |
31/12 |
| Acciones de libre circulación: |
70.60% |
| Fecha de OPI: |
09/03/1999 |
Relación con inversores
| Nombre: |
Dr. Julia Neugebauer |
| IR teléfono: |
+49 89 89927 179 |
| IR-fax: |
- |
| IR e-mail: |
investors@morphosys.com
|
